How tough is it getting for vaccine makers in the U.S.?

How tough is it getting for vaccine makers in the U.S.? is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-05-12

As federal policy chills domestic demand, some companies are increasingly leaning on sales from international markets.

Source: PharmaVoice